[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602724":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":24,"responsibleParty":36,"collaborators":24,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":24,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":24,"enrollmentInfo":49,"targetDuration":24,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":24,"overallStatus":58,"whyStopped":24,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":24},{"fullName":5,"class":6},"Hospital de Clínicas Dr. Manuel Quintela","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bisacodyl","EXPERIMENTAL","On the day prior to the procedure, the group receiving bisacodyl will take 4 tablets (5 mg each) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.",[13],"Drug: Bisacodyl 5 MG",{"label":15,"type":10,"description":16,"interventionNames":17},"Prucaloprida","On the day prior to the procedure, the group receiving prucalopride will take one 2 mg tablet at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation-that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.",[18],"Drug: Prucalopride 2mg",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Bisacodyl 5 MG",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Prucalopride 2mg","On the day prior to the procedure, the group receiving prucaloprida will take 1 tablet (2 mg) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Ignacio Moratorio","CONTACT","+59824871515","2397","ignacio.moratorio@gmail.com",{"type":37,"investigatorFullName":31,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Principal investigator","100602724","early-phase-1-prucaloprida-vs-bisacodyl-as-a-stimulant-in-bowel-preparation-for-video-colonoscopy-in-adults-100602724",false,"NCT07127237","Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults","Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults: A Randomized Clinical Trial","Inclusion Criteria:\n\n* All patients over 18 years of age.\n* Without prior colonic surgical interventions.\n* Who attend the Digestive Endoscopy service to undergo a colonoscopy.\n\nExclusion Criteria:\n\n* Patients who voluntarily choose not to participate in the study.\n* Pregnant women.\n* Patients with rectocolonic resections and\u002For ileostomies.\n* Inflammatory bowel disease.\n* Inadequate bowel preparation in a previous colonoscopy.\n* Suspected intestinal obstruction or perforation.\n* Intestinal intussusception.\n* Melena.\n* Oral iron intake within the last 10 days.\n* Emergency colonoscopies.\n* Hypersensitivity to any component of the bowel preparation solutions.\n* Chronic kidney disease on dialysis.\n* Uncorrected severe electrolyte imbalances.\n* Major psychiatric disorders.\n* Low intellectual quotient.\n* Severe constipation (≤ 1 bowel movement per week).\n* Chronic diarrhea with high frequency (≥ 4 daily bowel movements of uniformly decreased consistency for more than 4 weeks).\n* Decompensated cardiac diseases (ischemic heart disease, congestive heart failure, unstable angina, arrhythmias, and uncontrolled hypertension).\n* Ascites.",true,"ALL","18 Years",{"count":50,"type":51},124,"ESTIMATED","INTERVENTIONAL",[54],"EARLY_PHASE1","The objective of this randomized clinical trial is to compare prucalopride versus bisacodyl as a stimulant agent for bowel cleansing preparation prior to colonoscopy in patients undergoing the procedure at the Endoscopy Unit of the Hospital de Clínicas. The main research questions this study aims to answer are:\n\nIs prucalopride superior or equivalent to bisacodyl as a stimulant agent for bowel cleansing preparation before colonoscopy? Is the tolerability of prucalopride better, equivalent, or worse compared to bisacodyl? The investigators will compare the standard bowel cleansing preparation using polyethylene glycol (PEG) in combination with either bisacodyl or prucalopride as the stimulant agent.\n\nParticipants will be randomized into two groups, both receiving the same base preparation with different stimulant agents.",[57],"Bowel Preparation","NOT_YET_RECRUITING","2025-08-11",{"date":61,"type":62},"2025-08-17","ACTUAL",{"date":64,"type":51},"2025-09",{"date":66,"type":51},"2026-02",{"name":5,"class":6}]